Details of Disease

General Information of Disease (ID: DISXUI9P)

• Disease Name: rubella
• Synonyms: three day measles; Rubella virus disease or disorder; three-Day Measles; Rubella virus caused disease or disorder; Rubella virus infectious disease; german measles; Rubella infection
• Disease Class: 1F02: Rubella
• Definition: A viral infection caused by the rubella virus. It is initially manifested with flu-like symptoms that last one or two days, followed by the development of a characteristic red rash which lasts from one to five days. The rash first appears in the neck and face. It subsequently spreads to the rest of the body.
• Disease Hierarchy:
  DISDI77C: Primary viral infectious disease
  DISEM33Q: Infectious disease
  DISXUI9P: rubella
• ICD Code: ICD-11: ICD-11: 1F02
• Disease Identifiers:
  MONDO ID: MONDO_0004656
  MESH ID: D012409
  UMLS CUI: C0035920
  MedGen ID: 48514
  SNOMED CT ID: 36653000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GSK4406371A	DMGKKR9	Phase 2	Vaccine	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 6 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
EBI3	TTJF68X	Strong	Biomarker	[2]
HDC	TTV9GOF	Strong	Biomarker	[3]
IL10RB	TTJTRMK	Strong	Biomarker	[2]
MOG	TTQAFX5	Strong	Biomarker	[4]
MRC1	TTKV8W5	Strong	Genetic Variation	[5]
TGM1	TT7A949	Strong	Genetic Variation	[6]

This Disease Is Related to 23 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
MFSD6	OTQ6KAV1	moderate	Genetic Variation	[7]
ARFGEF1	OTPAU0L4	Strong	Biomarker	[8]
ARID2	OTIRJXWM	Strong	Biomarker	[8]
BTN2A1	OTUYPMZJ	Strong	Biomarker	[2]
BTN3A3	OTKMSJRA	Strong	Biomarker	[2]
CANX	OTYP1F6J	Strong	Biomarker	[9]
CCDC8	OTO295IH	Strong	Biomarker	[9]
CCL14	OT8QETQU	Strong	Altered Expression	[10]
CHAF1A	OTXSSY4H	Strong	Biomarker	[11]
CIAO3	OT0V91PK	Strong	Biomarker	[12]
CIP2A	OTVS2GXA	Strong	Biomarker	[9]
CTR9	OTP151PZ	Strong	Biomarker	[11]
ELP1	OTYEWBF7	Strong	Biomarker	[11]
HLA-DRB5	OTUX5TWM	Strong	Biomarker	[13]
IL18R1	OT83XMPQ	Strong	Biomarker	[2]
LAMP3	OTN0XL3W	Strong	Biomarker	[14]
LSAMP	OTYXVQX2	Strong	Biomarker	[14]
NDUFS4	OTJKUYEE	Strong	Biomarker	[15]
OAS1	OT8ZLOCY	Strong	Genetic Variation	[16]
PIK3R4	OTRL8QP8	Strong	Biomarker	[11]
RAB3GAP2	OTQTE0GI	Strong	Biomarker	[11]
SAG	OTDNS3ZQ	Strong	Biomarker	[17]
SMOC1	OTJG2JQY	Strong	Genetic Variation	[16]

References

• [1] Clinical pipeline report, company report or official report of GlaxoSmithKline
• [2] Genetic polymorphisms associated with rubella virus-specific cellular immunity following MMR vaccination.Hum Genet. 2014 Nov;133(11):1407-17. doi: 10.1007/s00439-014-1471-z. Epub 2014 Aug 7.
• [3] Persistent rubella infection after erroneous vaccination in an immunocompromised patient with acute lymphoblastic leukemia in remission.J Med Virol. 1995 Dec;47(4):442-4. doi: 10.1002/jmv.1890470425.
• [4] Myelin Oligodendrocyte Glycoprotein-Independent Rubella Infection of Keratinocytes and Resistance of First-Trimester Trophoblast Cells to Rubella Virus In Vitro.Viruses. 2018 Jan 4;10(1):23. doi: 10.3390/v10010023.
• [5] Coverage rates and timeliness of nationally recommended vaccinations in Swiss preschool children: A descriptive analysis using claims data.Vaccine. 2020 Feb 5;38(6):1551-1558. doi: 10.1016/j.vaccine.2019.11.057. Epub 2019 Nov 30.
• [6] Mapping of a second locus for lamellar ichthyosis to chromosome 2q33-35.Hum Mol Genet. 1996 Apr;5(4):555-9. doi: 10.1093/hmg/5.4.555.
• [7] A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration.Hum Vaccin Immunother. 2019;15(4):786-799. doi: 10.1080/21645515.2018.1554971. Epub 2019 Feb 20.
• [8] Determinants in the maturation of rubella virus p200 replicase polyprotein precursor.J Virol. 2012 Jun;86(12):6457-69. doi: 10.1128/JVI.06132-11. Epub 2012 Apr 4.
• [9] Analysis of the function of cytoplasmic fibers formed by the rubella virus nonstructural replicase proteins.Virology. 2010 Oct 25;406(2):212-27. doi: 10.1016/j.virol.2010.07.025. Epub 2010 Aug 8.
• [10] Gene expression profiling of rubella virus infected primary endothelial cells of fetal and adult origin.Virol J. 2016 Feb 2;13:21. doi: 10.1186/s12985-016-0475-9.
• [11] Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology.PLoS One. 2017 Nov 16;12(11):e0188149. doi: 10.1371/journal.pone.0188149. eCollection 2017.
• [12] Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.Vaccine. 2017 May 25;35(23):3116-3122. doi: 10.1016/j.vaccine.2017.04.027. Epub 2017 Apr 28.
• [13] HLA antigens and antibody responses to measles and rubella viruses in multiple sclerosis.Acta Neurol Scand. 1977 Apr;55(4):299-309. doi: 10.1111/j.1600-0404.1977.tb05649.x.
• [14] Development of an improved RT-LAMP assay for detection of currently circulating rubella viruses.J Virol Methods. 2014 Oct;207:73-7. doi: 10.1016/j.jviromet.2014.06.013. Epub 2014 Jun 24.
• [15] Congenital viral infections in England over five decades: a population-based observational study.Lancet Infect Dis. 2020 Feb;20(2):220-229. doi: 10.1016/S1473-3099(19)30416-5. Epub 2019 Nov 7.
• [16] 2'-5'-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine.Hum Immunol. 2010 Apr;71(4):383-91. doi: 10.1016/j.humimm.2010.01.004. Epub 2010 Jan 31.
• [17] Preliminary multiplex microarray IgG immunoassay for the diagnosis of toxoplasmosis and rubella.Mem Inst Oswaldo Cruz. 2017 Jun;112(6):428-436. doi: 10.1590/0074-02760160509.